Evidence map›Paper›PMID 25540362›Full record

ArticleJournal of virology2015

RNase L targets distinct sites in influenza A virus RNAs.

Daphne A Cooper, Shuvojit Banerjee, Arindam Chakrabarti, Adolfo García-Sastre, Jay R Hesselberth, Robert H Silverman, David J Barton

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 62 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. A CRISPR-Cas9 knockout screening identifies IRF2 as a key driver of OAS3/RNase L-mediated RNA decay during viral infection.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  9. Article
  10. Review
  11. Review
  12. Role of CIV NS1 Protein in Innate Immunity and Viral Replication.International journal of molecular sciences · 2023
    Article
  13. Article
  14. Review
  15. Phospho-RNA sequencing with circAID-p-seq.Nucleic acids research · 2022
    Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Daphne A CooperDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, Colorado, USA.
Shuvojit BanerjeeDepartment of Cancer Biology, Lerner Research Institute, The Cleveland Clinic, Cleveland, Ohio, USA.
Arindam ChakrabartiDepartment of Cancer Biology, Lerner Research Institute, The Cleveland Clinic, Cleveland, Ohio, USA.
Adolfo García-SastreDepartment of Microbiology, Department of Medicine, Division of Infectious Diseases, Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Jay R HesselberthDepartment of Biochemistry and Molecular Genetics, University of Colorado School of Medicine, Aurora, Colorado, USA Program in Molecular Biology, University of Colorado School of Medicine, Aurora, Colorado, USA.
Robert H SilvermanDepartment of Cancer Biology, Lerner Research Institute, The Cleveland Clinic, Cleveland, Ohio, USA.
David J BartonDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, Colorado, USA Program in Molecular Biology, University of Colorado School of Medicine, Aurora, Colorado, USA david.barton@ucdenver.edu.
Cleveland Clinic Lerner College of Medicine · USUniversity of Colorado Denver · USIcahn School of Medicine at Mount Sinai · US

Funding

University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
Colorado Clinical and Translational Sciences InstituteUL1TR001082 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2013 to 2017
$48.0M
Virus CoreU19AI106754 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI CHANDA, SUMIT K · 2013 to 2017
$26.0M
Enterovirus RNA Translation and ReplicationR01AI042189 · NIAID · UNIVERSITY OF COLORADO DENVER · PI BARTON, DAVID J · 1998 to 2024
$7.2M
REGULATION OF 2-5A-DEPENDENT RNASE LEVELS OF INTERFERONR01CA044059 · NCI · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · PI SILVERMAN, ROBERT H. · 1986 to 2015
$6.1M
Molecular Pathogenesis of Infectious DiseasesT32AI052066 · NIAID · UNIVERSITY OF COLORADO DENVER · PI VAN DYK, LINDA F. · 2002 to 2022
$2.3M
Enterovirus RNA Translation and ReplicationR56AI042189 · NIAID · UNIVERSITY OF COLORADO DENVER · PI BARTON, DAVID J · 2009 to 2009
$341k
Enterovirus RNA Translation and ReplicationR21AI042189 · NIAID · UNIVERSITY OF COLORADO DENVER · PI BARTON, DAVID J · 2003 to 2003
$268k
NCATS NIH HHS UL1 TR001082NCI NIH HHS P30 CA046934NCI NIH HHS R01 CA044059NIAID NIH HHS HHSN272201400008CNIAID NIH HHS R01 AI042189NIAID NIH HHS R21 AI042189NIAID NIH HHS R56 AI042189NIAID NIH HHS T32 AI052066NIAID NIH HHS U19 AI106754
6 · The paper itself

Abstract

unlabelledInfluenza A virus (IAV) infections are influenced by type 1 interferon-mediated antiviral defenses and by viral countermeasures to these defenses. When IAV NS1 protein is disabled, RNase L restricts virus replication; however, the RNAs targeted for cleavage by RNase L under these conditions have not been defined. In this study, we used deep-sequencing methods to identify RNase L cleavage sites within host and viral RNAs from IAV PR8ΔNS1-infected A549 cells. Short hairpin RNA knockdown of RNase L allowed us to distinguish between RNase L-dependent and RNase L-independent cleavage sites. RNase L-dependent cleavage sites were evident at discrete locations in IAV RNA segments (both positive and negative strands). Cleavage in PB2, PB1, and PA genomic RNAs suggests that viral RNPs are susceptible to cleavage by RNase L. Prominent amounts of cleavage mapped to specific regions within IAV RNAs, including some areas of increased synonymous-site conservation. Among cellular RNAs, RNase L-dependent cleavage was most frequent at precise locations in rRNAs. Our data show that RNase L targets specific sites in both host and viral RNAs to restrict influenza virus replication when NS1 protein is disabled. IMPORTANCE: RNase L is a critical component of interferon-regulated and double-stranded-RNA-activated antiviral host responses. We sought to determine how RNase L exerts its antiviral activity during influenza virus infection. We enhanced the antiviral activity of RNase L by disabling a viral protein, NS1, that inhibits the activation of RNase L. Then, using deep-sequencing methods, we identified the host and viral RNAs targeted by RNase L. We found that RNase L cleaved viral RNAs and rRNAs at very precise locations. The direct cleavage of IAV RNAs by RNase L highlights an intimate battle between viral RNAs and an antiviral endonuclease.

Indexed as

Host-Pathogen InteractionsCell LineEndoribonucleasesEpithelial CellsGene Knockdown TechniquesHigh-Throughput Nucleotide SequencingHumansHydrolysisInfluenza A virusRNA StabilityRNA, ViralVirus Replication2-5A-dependent ribonucleaseEndoribonucleasesRNA, Viral

Identifiers

PMID25540362
PMCPMC4325751
OpenAlexW2077523678

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.